research Comparison Of Single And Double-Spin Platelet- Rich Plasma Therapy For Treating Androgenetic Alopecia In Males: A Double-Blinded Randomized Controlled Trial
Double-spin PRP is more effective for treating male pattern baldness.
Search
for
Sort by
Research
210-240 / 1000+ results research Association of HSPA1B SNP rs6457452 with Alopecia Areata in the Korean Population
The SNP rs6457452 is linked to a higher risk of alopecia areata in Koreans.
research The Efficacy of Platelet-Rich Plasma in the Treatment of Androgenetic Alopecia: A Pilot Study
research Efficacy of Oral Apremilast in The Treatment of Alopecia Areata, at The Tertiary Care Hospital, Karachi
Oral Apremilast effectively treats alopecia areata in most patients.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research COMPARATIVE EFFICACY OF TOPICAL CLOBETASOL PROPIONATE 0.05% OINTMENT AND TOPICAL TACROLIMUS 0.1% OINTMENT IN THE TREATMENT OF ALOPECIA AREATA
Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
research Research progress of platelet-rich plasma in the treatment of androgenetic alopecia
PRP shows promise in treating hair loss by promoting cell growth.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
research CXCL12 Neutralizing Antibody Promotes Hair Growth in Androgenic Alopecia and Alopecia Areata
Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.
research Male Androgenetic Alopecia
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research Localized corticosteroid delivery in alopecia areata using microneedle patch technology
research Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata
The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.
research Design and Characterization of Baricitinib Incorporated PLA 3D Printed Pills by Fused Deposition Modeling: An Oral Pill for Treating Alopecia Areata
The study created 3D-printed pills that effectively release a hair loss treatment drug over 24 hours.
research Nonscarring Alopecias
research Identification of Platelet Rich Plasma (PRP) Hair losses Prevent: A Study in Birdem General Hospital, Dhaka, Bangladesh
PRP is effective for treating hair loss in men.
research A proposal of an effective platelet-rich plasma protocol for the treatment of androgenetic alopecia
The document concludes that injecting platelet-rich plasma can effectively treat androgenetic alopecia, a type of hair loss.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research ALA-PDT in the Treatment of Diseases of Hair Follicles and Sebaceous Glands
research “Cold” X5 Hairlaser™ used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study
The X5 Hairlaser might help treat male hair loss, but more research is needed.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Baricitinib-loaded separable microneedle array patch (S-MAP) based on hyaluronic acid for alopecia areata therapy
The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
research Quality of life in alopecia areata: A disease specific questionnaire
Alopecia areata greatly affects quality of life, needing psychological support.
research Treatment for androgenetic alopecia with microneedling along with platelet rich plasma
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Double-Blind, Placebo-Controlled Pilot Study on the Use of Platelet-Rich Plasma in Women With Female Androgenetic Alopecia
PRP may help treat female hair loss, but more research needed.
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.